Epstein–Barr virus protein EB2 stimulates cytoplasmic mRNA accumulation by counteracting the deleterious effects of SRp20 on viral mRNAs

Franceline Juillard1,2,3, Quentin Bazot1,2,3, Fabrice Mure1,2,3, Lionel Tafforeau3,4, Christophe Macri1,2,3, Chantal Rabourdin-Combe3,4, Vincent Lotteau3,4, Evelyne Manet1,2,3,* and Henri Gruffat1,2,3,*

1INSERM U758, Unité de Virologie Humaine, 69364 Lyon, France, 2Ecole Normale Supérieure de Lyon, 69364 Lyon, France, 3Université de Lyon, 69361 Lyon, France and 4INSERM U851, IMAP Team, 69365 Lyon, France

Received January 4, 2012; Revised March 19, 2012; Accepted March 23, 2012

ABSTRACT

The Epstein–Barr Virus (EBV) protein EB2 (also called Mta, SM and BMLF1), is an essential nuclear protein produced during the replicative cycle of EBV. EB2 is required for the efficient cytoplasmic accumulation of viral mRNAs derived from intronless genes. EB2 is an RNA-binding protein whose expression has been shown to influence RNA stability, splicing, nuclear export and translation. Using a yeast two-hybrid screen, we have identified three SR proteins, SF2/ASF, 9G8 and SRp20, as cellular partners of EB2. Then, by using siRNA to deplete cells of specific SR proteins, we found that SRp20 plays an essential role in the processing of several model mRNAs: the Renilla luciferase reporter mRNA, the human β-globin cDNA transcript and two EBV late mRNAs. These four mRNAs were previously found to be highly dependent on EB2 for their efficient cytoplasmic accumulation. Here, we show that SRp20 depletion results in an increase in the accumulation of these mRNAs, which correlates with an absence of additive effect of EB2, suggesting that EB2 functions by antagonizing SRp20. Moreover, by using RNA-immunoprecipitation assays we found that EB2 enhances the association of SRp20 with the β-globin transcript suggesting that EB2 acts by stabilizing SRp20’s labile interactions with the RNA.

INTRODUCTION

In eukaryotic cells, nuclear export of mRNAs is mediated by conserved proteins which coat the nascent RNA co-transcriptionally to form export-competent mRNPs that are capped at their 5'-end, spliced, and cleaved/polyadenylated at their 3'-end [for a review, see (1)]. Translocation of mRNPs through the nuclear pore complex requires binding of a heterodimer composed of NXF1 and NXT1 (respectively Mex67 and Mtr2 in Saccharomyces cerevisiae), which escorts competent mRNPs out of the nucleus via direct interactions with nucleoporins lining the nuclear pore. Because of its low affinity for binding mRNAs, the heterodimer NXF1:NXT1 requires adaptator proteins, amongst which the best characterized is REF (2). In higher eukaryotes the recruitment of NXF1:NXT1 to mature mRNAs appears to be dependent upon 5'-cap addition and splicing. Two multiprotein complexes are known to be recruited as a consequence of splicing: the exon–junction complex (EJC) which is deposited 20–24 nt upstream of the exon–exon junction during splicing and which is associated with nonsense-mediated mRNA decay (NMD), and the human transcription/export complex (hTREX). hTREX contains the hTHO-complex (composed of hHpr1, hTho2, fSAP79, fSAP35 and fSAP24) associated with the RNA helicase UAP56 and the adaptator protein REF. Recent studies strongly suggest that the cap-binding protein CBP80 and factors deposited at the first exon–exon junction by splicing, cooperate to recruit hTREX onto spliced mRNAs (3). The presence of REF in this complex is
thought to stimulate the recruitment of NXF1 onto the mRNPs and lead to their efficient export through the nuclear pore.

For mRNAs generated from intronless genes, two export pathways have been described. One implicates binding of SR proteins 9G8 and SRp20 to mRNAs (4). Similarly to REF, these two shuttling SR proteins have been found to serve as RNA-binding adaptors for NXF1 (5). The other pathway implicates recruitment of REF at the S′-end of the mRNA by the cap-binding protein CBP20 (6).

In contrast to the majority of mammalian genes, most herpesvirus early and late genes are intronless. The efficient cytoplasmic accumulation of most of these intronless viral mRNAs appears to be strictly dependent on a viral gene product that shares properties with known mRNA export adaptors. The most studied of these factors are the herpes simplex virus type 1 (HSV1) protein ICP27 (7,8), the cytomegalovirus (CMV) protein UL69 (9), and the Kaposi’s sarcoma-associated herpes virus (KSHV) protein ORF57 (10,11), the herpes virus saimiri (HVS) protein ORF57 (12), the Varicella-Zoster virus (VZV) protein IE4 (13) and the Epstein–Barr virus (EBV) protein EB2 (also known as BMLF1, SM and Mta) (14,15). The EB2 protein of EBV is absolutely required for production of infectious viral particles (16). It binds RNA in vitro and in vivo via an arginine-rich region (17) and induces the cytoplasmic accumulation of most early and late viral mRNAs (16,18,19) both by interacting with cellular adaptors of the NXF1/NXT1 receptor pathway such as REF (20) or OTT1/RBM15 and OTT3/RBM15b (21), two RNA-binding proteins that belong to the human Spen (split end) protein family (22,23), and by directly interacting with NXF1 (24). Like cellular mRNA export factors, EB2 shuttles between the nucleus and the cytoplasm (14,20,24) and we have recently shown that it associates with polyribosomes and strongly stimulates translation of its target mRNAs (25). Moreover, it has recently been shown that EB2/SM modulates splice site selection of the host-cell STAT1 mRNA by the action of SR proteins.

In order to better understand the mechanisms involved in the multiple functions of EB2, both in viral mRNA processing and translation, we used a wide yeast two-hybrid screen to identify the principal interactions of EB2 with the cellular proteome. Interestingly, we found specific interactions with three members of the SR protein family: SF2/ASF (SRSF1), SRp20 (SRSF3) and 9G8 (SRSF7). The SR protein family comprises a number of phylogenetically conserved and structurally related proteins. They have a common organization with the presence of one or two RNA recognition motifs (RRMs) at their N-termini that provide RNA-binding specificity, and a domain rich in arginine and serine dipeptides, termed the RS domain, at their C-termini. SR proteins have specific, yet degenerate RNA-binding sites. They were originally identified due to their activities as constitutive and alternative pre-mRNA splicing factors [for a review see (28,29)]. However, a subset of SR proteins, which includes SF2/ASF, SRp20 and 9G8, has been found to play additional roles in RNA processing. For example, SF2/ASF has been implicated in mRNA translation of an ESE (exonic splicing enhancer)-containing luciferase reporter (30,31), SRp20 has been shown to function in IRES (internal ribosome entry site)-mediated translation of viral RNA (32) and 9G8 in translation of un-spliced mRNA containing a CTE (constitutive transport element) (33). Moreover, SRp20 and 9G8 have been found to function in the nucleocytoplasmic export of mRNA by interacting with the mRNA nuclear export factor NXF1 (4,5).

After confirming the interactions found in the two-hybrid screen between EB2 and the three SR proteins by GST–pull-down and co-immunoprecipitation assays, we have studied the impact of depletion of these SR proteins from cells for the EB2-dependent cytoplasmic accumulation of two model transcripts generated from intronless reporter genes as well as two late viral mRNAs and virus particle production. Our results have led us to propose a new mechanism by which a viral protein enhances mRNA accumulation by antagonizing the action of SR proteins.

**MATERIALS AND METHODS**

**Human lymphoblastoid cell cDNA library**

Human peripheral blood mononuclear cells (PBMC) were freshly isolated by density-gradient centrifugation using Ficoll Hypaque (Sigma). B cells were purified from the PBMCs using anti-CD19 coated nanoparticles (EasySep, Stem Cell Technologies). Purified B cells were infected with a recombinant EBV expressing GFP as previously described (34) and infected cells were selected by hygromycin treatment. After several weeks in culture the resulting immortalized cells were used to generate a cDNA library in pACT2-GW (Invitrogen) (1.33 × 10⁷ primary clones).

**Plasmids**

ORFs for full-length EB2, EB2Nter (amino acids 1–184) and EB2Cter (amino acids 185–479) were cloned in a Gateway recombinational cloning system (35) and deposited in a viral ORF repository, viralORFeome (36). Each ORF was PCR-amplified (with KOD polymerase, Novagen) using attB1 and attB2 recombinasion sites fused to forward and reverse primers, then cloned into pDONR207 (BP Clonase, Invitrogen). The ORFs were subsequently transferred (LR Clonase, Invitrogen) into the bait vector, pGBK7T, to be expressed as Gal4-DB fusions in yeast. Plasmids pCI-FlagEB2, pCI-FlagEB2Nter, pCI-FlagEB2Cter, pCI-FlagEB2 M1.2, pCI-FlagEB2Nter M1.2, pGEX-EB2Nter and pGEX-EB2Cter have been previously described (20,37), pGEX-SRp20, pGEX-9G8, pGEX-SF2/ASF have also been previously described (13). pGEX-SRp20 was constructed by insertion of a stop codon at position 104 in pGEX-SRp20 by site-directed mutagenesis (QuickChange Site-Directed Mutagenesis kit, Stratagene). pGEX-SRp20 RS was generated by cloning a PCR-amplified SRp20 fragment into the pDEST15 vector (Invitrogen) using Gateway technology (Invitrogen). pDEST-MycNXF1 was generated by cloning a PCR-amplified fragment
into the pDEST-Myc vector (Invitrogen) using Gateway technology (Invitrogen). Expression plasmids for HA-SRP20, V5-SRP20, V5-9G8 and V5-SF2/ASF have been previously described (13) as well as plasmid pcDNAGlobinRen (25). Plasmids β1(−2)(−), 1X-βG, 2X-βG and 4X-βG were a kind gift from Dr Y. Huang. Plasmid pCl-FlagBFRF3-i has been previously described (18). Plasmid pCl-FlagBDLF1-i was constructed in a similar way to pCl-FlagBFRF3-i.

Yeast two-hybrid screens

The screens were performed by yeast mating using the AH109 and Y187 yeast strains (Clontech) (38,39). Bait vectors, pGBK7T-EB2, pGBK7T-EB2Nter, pGBK7T-EB2Cter were transformed into AH109 (bait strain), and the human lymphoblastoid cell line AD–cDNA library was transformed into Y187 (prey strain). Single bait strains were mated with prey strain and then diploids were plated on SD-W-L-H+5 mM 3-AT medium. Positive clones were maintained on this selective medium for 15 days to eliminate any contaminating AD–cDNA plasmid (40). AD–cDNAs were amplified by colony PCR and inserts were sequenced and identified by automatic BLAST as previously described (41). All primary positive clones were then restested in fresh yeast: bait vectors were retransformed in the AH109 strain and PCR-amplified prey cDNA (for each identified putative interactor) was transformed in the Y187 strain in combination with linearized pACT2 prey vector [gap repair (42)]. All prey strains were then mated with the different bait strains in an ‘all against all’ fashion, generating a Y2H pairwise matrix.

Cell culture and transfections

HeLa cells and HEK293T cells were grown at 37°C in DMEM supplemented with 10% Foetal Bovine Serum (FBS) and penicillin–streptomycin. HEK293 cells infected with the recombinant EBV virus (HEK293EBV), a gift from Dr W. Hammerschmidt, have been described previously (43). The recombinant virus encodes Green Fluorescent Protein (GFP) and the hygromycin B resistance gene. HEK293EBV cells or HEK293 EBV-BMLF1KO cells were transfected with pCMV-BZLF1, an expression vector coding for the EBV transcriptional activator EB1 (also called Zta or Zebra), to activate the EBV productive cycle. Supernatants from transfected cells were harvested at 48 h post-transfection and filtered through a 0.45-μm pore size filter. Raji cells (1 × 10⁵) were incubated in 0.5 ml of virus solution for 6–8 h at 37°C in a 24-well plate. Cells were then washed, re-suspended in 1 ml of RPMI and incubated for an additional 72 h at 37°C. GFP-expressing Raji cells were quantified by FACs analysis.

Co-immunoprecipitation assays and western blots

Transfected HEK293T cells were harvested from 100-mm dishes 48 h post-transfection and lysed in IP buffer (50 mM Tris–HCl pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 mM DTT and 0.5% Nonidet P-40) plus protease inhibitors (Roche Molecular Biochemicals) and phosphatase inhibitors (Phosphatase Inhibitor Cocktail 2, Sigma-Aldrich). For immunoprecipitation of the transiently expressed F. EB2 protein, cell extracts were incubated with 30 μl anti-Flag M2 affinity gel (Sigma) for 4 h at 4°C and immunopurified proteins were analysed by western blotting. Antibodies used for western blotting analysis were an anti-Flag rabbit polyclonal antibody (Sigma), an anti-V5 rabbit polyclonal antibody (Sigma), an anti-SRP20 mAb (clone 7B4, Invitrogen), an anti-9G8 rabbit polyclonal antibody (Sigma), an anti-SF2/ASF mAb (clone 96, Invitrogen) and an anti-α-Tubulin mAb (B-5-1-2, Sigma). The appropriate anti-mouse or anti-rabbit horseradish peroxidase (HRP)-conjugated antibodies (GE healthcare) were used as secondary antibodies. Myc-tagged proteins were revealed using a c-Myc (9E10) HRP-conjugated antibody (Santa Cruz). RNase treatment was performed by adding 2 μl of RNase A (10 mg/ml) to each reaction. Western blots were revealed using ECL (Pierce).

In vitro GST pull-down assays

GST and GST-fusion proteins were purified from Escherichia coli BL21 (DE3) codon plus strain extracts, with glutathione–Sepharose 4B beads (Amersham Biosciences). Beads carrying the GST or the GST-fusion proteins were equilibrated in TNTB-binding buffer (10 mM Tris–HCl pH 8, 250 mM NaCl, 0.1% NP40 and 2 mg/ml BSA) in the presence of protease inhibitors (complete EDTA-free cocktail from Roche Molecular Biochemicals) and incubated with radiolabelled proteins synthesized in vitro in the presence of [³⁵S]-methionine using the TntT-Coupled Transcription/Translation system (Promega), in TNTB for 4 h at 4°C. RNase treatment was performed by adding 1 μl of RNase A (10 mg/ml) and 1 μl of RNase T1 (10 U/μl) in the incubation reaction. Beads were washed 5× in TNTB buffer without BSA and bound

Virus production and titration

HEK293EBV cells or HEK293EBV-BMLF1KO cells were transfected with pCMV-BZLF1, an expression vector coding for the EBV transcriptional activator EB1 (also called Zta or Zebra), to activate the EBV productive cycle. Supernatants from transfected cells were harvested at 48 h post-transfection and filtered through a 0.45-μm pore size filter. Raji cells (1 × 10⁵) were incubated in 0.5 ml of virus solution for 6–8 h at 37°C in a 24-well plate. Cells were then washed, re-suspended in 1 ml of RPMI and incubated for an additional 72 h at 37°C. GFP-expressing Raji cells were quantified by FACs analysis.
proteins were fractionated by SDS–PAGE and revealed by autoradiography

**Immunofluorescence assays**

For indirect immunofluorescence experiments, an anti-Flag polyclonal antibody (Sigma) and an anti-HA mAb (Sigma) were used as primary antibodies. Alexa Fluor 488 goat anti-rabbit antibody (Invitrogen) and a Fluorolink Cy3-labelled goat anti-mouse IgG (H+L) (GE Healthcare) were used as secondary antibodies. Cell nuclei were stained by incubation with 5 μg/ml Hoescht 33258 (Sigma).

**RT–PCR amplifications and RNA immunoprecipitations**

RNA extractions, quantitative reverse transcription PCR (RT–qPCR) from nuclear and cytoplasmic RNAs were performed as previously described (25). For semi-quantitative RT–PCR, RNA was extracted using TRIzol from Quanta (RT) and GoTaq DNA polymerase (Invitrogen). Any contaminating DNA was removed from quantitative RT–PCR, RNA was extracted using TRIzol were performed as previously described (25). For semi-quantitative RT–PCR from nuclear and cytoplasmic RNAs. 33258 (Sigma).

Immunofluorescence assays

For indirect immunofluorescence experiments, an anti-Flag polyclonal antibody (Sigma) and an anti-HA mAb (Sigma) were used as primary antibodies. Alexa Fluor 488 goat anti-rabbit antibody (Invitrogen) and a Fluorolink Cy3-labelled goat anti-mouse IgG (H+L) (GE Healthcare) were used as secondary antibodies. Cell nuclei were stained by incubation with 5 μg/ml Hoescht 33258 (Sigma).

**RESULTS**

**Identification of the three SR proteins, 9G8, SF2/ASF and SRp20 as specific interactors of the EBV EB2 protein in a yeast two-hybrid screen**

We used the yeast two-hybrid (Y2H) system to identify cellular proteins that interact with EB2. Three constructs, encoding full length, N-terminal half (amino acids 1–184) or C-terminal half (amino acids 185–497) of EB2 were used to probe a human lymphoblastoid cell line (EBV-infected) cDNA library. Three independent screens were performed with each EB2-derived bait protein by mating. In total, each EB2 construct was screened against 2–8 × 10⁷ human AD–Y fusion proteins and 269 clones (corresponding to 64 different putative interactions) were initially characterized following PCR amplification of the cDNAs and sequencing. The data set was retested by direct Y2H between EB2 protein baits and cellular protein preys identified by our Y2H screens (Y2H pairwise matrices). After elimination of autoactivators, 43 Y2H interactors were retested positive (Table 1). From the 269 initial positive colonies, 80 corresponded to an interaction of EB2 with itself via its C-terminal domain. In our list of cellular interactors, only Sp100 (46) and RBM15B (21) have been previously described as direct interactors for EB2. A majority of the newly identified interactors corresponds to proteins involved in RNA metabolism. Among them, we found three members of the highly conserved SR protein family, namely 9G8 (SFRS7), SF2/ASF (SFRS1) and SRp20 (SFRS3). To confirm the interaction between EB2 and the three SR proteins in mammalian cells, we performed co-immunoprecipitation assays. V5-tagged 9G8, SF2/ASF, SRp20—or Myc-tagged NXF1 as a positive control—were expressed in HEK293T cells either alone or together with Flag-tagged EB2. Immunoprecipitations were performed using an M2 anti-Flag mAb affinity gel in the presence or absence of RNase and the immunoprecipitated complexes were analysed by western blotting. As published previously (24), NXF1 was efficiently co-immunoprecipitated with EB2 and the interaction was found to be drastically reduced in the presence of RNase (Figure 1D). Interestingly, 9G8 (panel A), SF2/ASF (panel B) and SRp20 (panel C) were all specifically co-immunoprecipitated with EB2 both in the presence or absence of RNase treatment indicating that all three SR proteins can interact with EB2 in mammalian cells and that these interactions are largely independent of the presence of RNA.

**EB2 interacts with 9G8, SF2/ASF and SRp20 via its C-terminal domain**

To confirm that EB2 interacts directly with the SR proteins and to identify the region of EB2 that is involved in each interaction, we performed in vitro binding assays using GST fusion proteins produced in bacteria and 35S-proteins that were in vitro- translated in reticulocyte lysates. In a first series of experiments, 35S-labelled EB2, EB2Nter or EB2Cter (Figure 2A) were
incubated with GST, GST–9G8, GST–SF2/ASF or GST–SRp20 proteins bound to Glutathione Sepharose beads in the presence of RNase. As shown in Figure 2B, EB2 was efficiently retained on GST–9G8, GST–SF2/ASF and GST–SRp20 but not on GST alone, which strongly suggests a direct interaction between EB2 and each of the three SR proteins. When we used the C-terminal half of EB2 (EB2Cter) we observed that this protein was retained on both GST–9G8 and GST–SRp20, but less efficiently on GST–SF2/ASF. On the contrary, the N-terminal domain of EB2 (EB2Nter) was not retained on GST–9G8 or GST–SRp20, but a weak interaction was detected with GST–SF2/ASF. In a reverse series of experiments, **35S**-labelled 9G8, SF2/ASF or SRp20 were incubated with GST, GST–EB2Nter or GST–EB2Cter (Figure 2C). All three proteins were retained on GST–EB2Cter, whereas interaction with GST–EB2Nter was either non-detectable (SRp20) or much

### Table 1. List of cellular proteins interacting with EB2 identified in the Y2H screen

<table>
<thead>
<tr>
<th>NCBI GeneID</th>
<th>Nb of hits</th>
<th>Gene symbol</th>
<th>Full name</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>RNA metabolism</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6672</td>
<td>7</td>
<td>SP100</td>
<td>SP100 nuclear antigen</td>
</tr>
<tr>
<td>22827</td>
<td>9</td>
<td>PUB60</td>
<td>Poly-U-binding splicing factor 60kDa</td>
</tr>
<tr>
<td>8175</td>
<td>1</td>
<td>SF3A2</td>
<td>Splicing factor 3a, subunit 2, 66kDa</td>
</tr>
<tr>
<td>6426</td>
<td>3</td>
<td>SRSF1</td>
<td>Splicing factor, arginine/serine-rich 1</td>
</tr>
<tr>
<td>6432</td>
<td>1</td>
<td>SRSF7</td>
<td>Splicing factor, arginine/serine-rich 7, 35kDa</td>
</tr>
<tr>
<td>6428</td>
<td>10</td>
<td>SRSF3</td>
<td>Splicing factor, arginine/serine-rich 3</td>
</tr>
<tr>
<td>8233</td>
<td>3</td>
<td>ZRSR2</td>
<td>Zinc finger (CCCH type), RNA-binding motif and serine/arginine-rich 2</td>
</tr>
<tr>
<td>3183</td>
<td>20</td>
<td>HNRNPC</td>
<td>Heterogeneous nuclear ribonucleoprotein C (C1/C2)</td>
</tr>
<tr>
<td>29890</td>
<td>2</td>
<td>RBM15</td>
<td>RNA-binding motif protein 15B</td>
</tr>
<tr>
<td><strong>Ribosome components</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6138</td>
<td>13</td>
<td>RPL15</td>
<td>Ribosomal protein L15</td>
</tr>
<tr>
<td>6129</td>
<td>1</td>
<td>RPL7</td>
<td>Ribosomal protein L7</td>
</tr>
<tr>
<td>6142</td>
<td>6</td>
<td>RPL18A</td>
<td>Ribosomal protein 18A</td>
</tr>
<tr>
<td>91582</td>
<td>2</td>
<td>RPS19BP1</td>
<td>Ribosomal protein S19-binding protein 1</td>
</tr>
<tr>
<td>7311</td>
<td>1</td>
<td>UBA52</td>
<td>Ubiquitin A-52 residue ribosomal protein fusion product 1</td>
</tr>
<tr>
<td><strong>Transcriptional regulation</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10743</td>
<td>3</td>
<td>RAI1</td>
<td>Retinoic acid induced 1</td>
</tr>
<tr>
<td>30836</td>
<td>1</td>
<td>DNTTIP2</td>
<td>Deoxynucleotidyltransferase, terminal, interacting protein2</td>
</tr>
<tr>
<td>3663</td>
<td>8</td>
<td>IRF5</td>
<td>Interferon regulatory factor 5</td>
</tr>
<tr>
<td><strong>Ubiquitination</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9636</td>
<td>3</td>
<td>ISG15</td>
<td>ISG15 ubiquitin-like modifier</td>
</tr>
<tr>
<td>7329</td>
<td>4</td>
<td>UBE2I</td>
<td>Ubiquitin-conjugating enzyme E2I (UBC9 homologue, yeast)</td>
</tr>
<tr>
<td><strong>Others</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>118881</td>
<td>3</td>
<td>COMT1</td>
<td>Catechol-O-methyltransferase domain containing 1</td>
</tr>
<tr>
<td>8525</td>
<td>3</td>
<td>DGKZ</td>
<td>Diacylglycerol kinase ζ 104kDa</td>
</tr>
<tr>
<td>7266</td>
<td>1</td>
<td>DNAJC7</td>
<td>DnaJ (Hsp40) homologue, subfamily C, member 7</td>
</tr>
<tr>
<td>4050</td>
<td>5</td>
<td>LTB</td>
<td>Lymphotoxin β (TNF superfamily member 3)</td>
</tr>
<tr>
<td>5155</td>
<td>8</td>
<td>PDGFB</td>
<td>Sarcomia viral (+-sis oncogene homologue)</td>
</tr>
<tr>
<td>6643</td>
<td>2</td>
<td>SVX22</td>
<td>Sorting nexin 2</td>
</tr>
<tr>
<td>147</td>
<td>1</td>
<td>ADRA1A</td>
<td>Adrenergic receptor, α-1B- receptor</td>
</tr>
<tr>
<td><strong>Unknown function</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>81844</td>
<td>2</td>
<td>TRIM56</td>
<td>Tripartite motif-containing 56</td>
</tr>
<tr>
<td>55661</td>
<td>24</td>
<td>DDX27</td>
<td>DEAD (Asp-Glu-Ala-Asp) box polypeptide 27</td>
</tr>
<tr>
<td>79009</td>
<td>1</td>
<td>DDX30</td>
<td>DEAD (Asp-Glu-Ala-Asp) box polypeptide 30</td>
</tr>
<tr>
<td>23518</td>
<td>2</td>
<td>R3HDM1</td>
<td>R3H domain containing 1</td>
</tr>
<tr>
<td>51111</td>
<td>1</td>
<td>SUF420H1</td>
<td>Suppressor of variegation 4-20 homologue 1 (Drosophila)</td>
</tr>
<tr>
<td>65265</td>
<td>1</td>
<td>C8orf33</td>
<td>Chromosome 8 open reading frame 33</td>
</tr>
<tr>
<td>84273</td>
<td>2</td>
<td>C4orf14</td>
<td>Chromosome 4 open reading frame 14</td>
</tr>
<tr>
<td><strong>Zinc-finger proteins</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7738</td>
<td>1</td>
<td>ZNF184</td>
<td>Zinc-finger protein 184</td>
</tr>
<tr>
<td>63977</td>
<td>1</td>
<td>ZNF298</td>
<td>Zinc-finger protein 298</td>
</tr>
<tr>
<td>126295</td>
<td>2</td>
<td>ZNF53</td>
<td>Zinc-finger protein 57</td>
</tr>
<tr>
<td>10782</td>
<td>2</td>
<td>ZNF274</td>
<td>Zinc-finger protein 274</td>
</tr>
<tr>
<td>79759</td>
<td>1</td>
<td>ZNF668</td>
<td>Zinc-finger protein 668</td>
</tr>
<tr>
<td>163049</td>
<td>1</td>
<td>ZNF791</td>
<td>Zinc-finger protein 791</td>
</tr>
<tr>
<td>99687</td>
<td>1</td>
<td>ZNF251</td>
<td>Zinc-finger protein 251</td>
</tr>
<tr>
<td>55769</td>
<td>1</td>
<td>ZNF83</td>
<td>Zinc-finger protein 83</td>
</tr>
<tr>
<td>3104</td>
<td>1</td>
<td>ZBTB48</td>
<td>Zinc-finger and BTB domain containing 48</td>
</tr>
<tr>
<td><strong>Viral protein</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5176227</td>
<td>80</td>
<td>EB2</td>
<td>mRNA export factor EB2</td>
</tr>
</tbody>
</table>

*a*confirmed by coIP *in vivo.*

Each human gene is identified by its National Center for Biotechnology Information (NCBI) gene ID (first column), Gene symbol (third column) and full name (fourth column). The number of independent clones found in the Y2H screen for a given partner is indicated in the second column.
weaker (9G8 and SF2/ASF). From these experiments we conclude that the main interaction domain between EB2 and the three SR proteins is located in its C-terminal half.

We then asked which domain of SRp20 was involved in the interaction with EB2. For this, we generated two GST–SRp20 mutant fusion proteins: one of the fusion protein carries the N-terminal RRM (RRM) domain, the other carries the RS-rich C-terminal domain (Figure 3A). The results (Figure 3B) suggest that the...
interaction domain of SRp20 with EB2 is located within the first 103 amino acids, which corroborates the finding of Verma et al. (27).

Over-expression of SRp20, 9G8 and SF2/ASF induces the nuclear re-localization of cytoplasmic EB2 mutant derivatives

Although SRp20 has been previously described as a shuttling protein, it is mostly detected in the nucleus. EB2—a also a shuttling protein—is similarly predominantly found at steady state in the nucleus and we have previously characterized two nuclear localization signals of the protein in its N-terminal half: an EB2 protein with its first 184 amino acids deleted was mostly cytoplasmic. Furthermore, by mutating two sequences—KRRR (NLS1: amino acids 126–130) and KRR (NLS2: amino acids 143–145)—to alanines, the resulting protein, F.EB2 M1.2 was found to be partially cytoplasmic (20). We made use of these EB2 cytoplasmic mutants to ask whether over-expression of nuclear SRp20 in HeLa cells would induce a re-localization of cytoplasmic EB2 mutants into the nucleus. We thus co-expressed HA-tagged SRp20 with each one of the three EB2 mutant proteins depicted in Figure 4A. The respective localization of the proteins was then visualized by immunofluorescence. As shown in Figure 4B, SRp20 was efficiently over-expressed only in a subset of the transfected cells (compare panels a, d and g to panels c, f and i respectively). Interestingly, when we compared the localization of F.EB2 M1.2 between cells overexpressing or not SRp20, we found that F.EB2 M1.2 became fully nuclear in cells over-expressing SRp20 (Figure 4B, panel b). In accordance with this, similar results were obtained when we used the F.EB2Cter protein. This protein, mostly cytoplasmic in cells that did not over-express SRp20, was clearly concentrated in the nuclei of cells over-expressing the SR protein (Figure 4B, panel e). In order to determine if the translocation of cytoplasmic EB2 into the nucleus was due to a direct interaction with SRp20, we used the F.EB2Nter M1.2 protein, which does not contain the SRp20 interaction domain. Again, due to the mutation of the two NLS sequences, the protein was mostly cytoplasmic. This cytoplasmic localization was not affected by the presence or not, of over-expressed SRp20 (Figure 4B, panel h). Similar results were obtained with both SF2/ASF and 9G8 (data not shown). Taken together, these experiments indicate that EB2 interacts with the three SR proteins within live cells.

Down-regulation of SRp20 expression by siRNA results in a strong inhibition of the EB2-dependent cytoplasmic Renilla luciferase mRNA accumulation

Since we previously reported that EB2 significantly increases the amount of cytoplasmic Renilla luciferase mRNA expressed from an intronless construct (25), we asked whether the SR proteins SRp20, 9G8 or SF2/ASF could play a role in the EB2-dependent cytoplasmic accumulation of this specific mRNA. The Renilla luciferase reporter construct pcDNA3GlobinRen (Figure 5A) was thus transfected into HeLa cells, together or not, with
an expression plasmid for EB2 48 h after transfection of the cells with an siRNA specific for SRp20, 9G8, SF2/ASF or a control siRNA. Both the expression level of EB2 and the efficiency of SRp20, 9G8 or ASF/SF2 down-regulation by the specific siRNAs were verified by western blot analysis as shown in Figure 5B, C and D respectively. The amount of cytoplasmic luciferase mRNA was then quantified by RT–qPCR, normalized to the amount of GAPDH mRNA and plotted on the graphs presented in Figure 5E, F and G as relative mRNA amounts. As we published previously (25), we found that in cells transfected with a control siRNA, the presence of EB2 led to a strong increase (16 - to 27-fold) in the amount of Renilla luciferase mRNA (compare lane 2 to lane 1 in panels E, F and G). When we inhibited endogenous SRp20 expression with a specific siRNA, EB2 did not induce any increase in the amount of Renilla luciferase mRNA (compare lane 4 to lane 3 in panel E). However, it should be noted that depletion of SRp20, in the absence of EB2, induced a reproducible increase (on average 5-fold) in the amount of cytoplasmic Renilla luciferase mRNA (compare lane 3 to lane 1 in panel E). The results of concomitant quantification of Renilla luciferase nuclear mRNAs (Supplementary Figure S1) were very similar to those obtained with the cytoplasmic mRNAs: EB2 induced an increase in the amount of nuclear luciferase RNA (10-fold). So did SRp20 depletion by itself (9-fold) and, in this case of SRp20 depletion, EB2 did not increase the amount of nuclear luciferase RNA. In fact, EB2 rather induced a diminution of nuclear luciferase RNA in the absence of SRp20. This effect of SRp20 depletion on both the amount of nuclear and cytoplasmic Renilla luciferase mRNA, suggests that SRp20 targets this specific mRNA and either induces its destabilization or stimulates cryptic splicing, which eliminates part of the luciferase mRNA sequence, including that amplified in our RT–PCR reaction. Inhibition of either 9G8 or SF2/ASF expression (Figure 5C and D respectively) also affected EB2-mediated cytoplasmic accumulation of Renilla luciferase mRNA, although to a much lower extent. Moreover, in the absence of EB2, depletion of either 9G8 or SF2/ASF did not have any noticeable impact on the level of the Renilla luciferase mRNA (Figure 5F and G). The results of concomitant quantification of the nuclear Renilla luciferase RNAs fully mimicked the results of the quantification obtained with the cytoplasmic mRNAs (data not shown).

Taken together, these results strongly suggest that SR proteins—and in the case of this specific mRNA, in particular SRp20—are required for efficient EB2-dependent cytoplasmic accumulation of its target mRNAs.

**EB2 induces efficient cytoplasmic accumulation of human β-globin cDNA transcript in a SRp20-dependent manner**

In the Renilla luciferase mRNA model, SRp20 appears to be the main SR protein necessary for EB2-dependent
cytoplasmic accumulation of the mRNA. SRp20 could be necessary, either for the efficient recruitment/stabilization of EB2 to the RNA or on the contrary, SRp20 could be recruited/stabilized onto the RNA by EB2 and participate actively in the stabilization and export of the mRNP. Interestingly, Huang and Steitz previously demonstrated that SRp20 (and 9G8) interacts specifically with a 22-nt RNA element from the mouse histone H2a gene (Figure 6A) (4). Insertion of this 22-nt motif, upstream of the human β-globin cDNA sequence in reporter construct β1(−)2(−) (Figure 6B) inhibits cryptic splicing between the β-globin-coding sequence and vector sequences, improves polyadenylation efficiency and enhances nuclear export. These effects increased with the number of tandemly repeated copies of the 22-nt element in a synergistic manner (4). We thus took advantage of these reporter constructs to study the effect of EB2 in relation to the presence of well-identified SRp20/9G8-binding sites. The constructs depicted in Figure 6B were thus used in transient transfections, either alone or together with an expression plasmid for EB2. Cytoplasmic RNA was then isolated and analysed by RT–PCR. As expected from the previous results of Huang and Steitz (4), we observed that the amount of cytoplasmic β-globin mRNA increased with the multimerization of the 22-nt motif (Figure 6C, lanes 1, 3, 5 and 7). Interestingly, although EB2 increased the amount of cytoplasmic β-globin mRNA expressed from the four β-globin constructs (Figure 6C, lane 2), we observed that this effect was inversely proportional to the number of 22-nt motifs present in the reporter constructs (Figure 6C, lanes 2, 4, 6 and 8 and Figure 6D).

We then asked whether the effect of EB2 on the β1(−)2(−) RNA was dependent on SRp20 by reiterating the above experiments in the presence of an anti-SRp20 siRNA or a control siRNA. The data presented in Figure 7, show that the EB2-induced increase in the cytoplasmic accumulation of the β-globin mRNA expressed from the β1(−)2(−) construct, is strongly dependent on the presence of SRp20. Similarly to what we observed with the Renilla luciferase mRNA, we noted a reproducible increase in the amount of cytoplasmic β-globin mRNA when the cells were depleted of SRp20. This was not due to an indirect effect on the level of transcription initiated at the β-globin promoter since we did not observe any difference in the amount of transcripts generated from the 4x-βG construct that contains the 22-nt ‘stabilizing’ motif (data not shown). We also tested the impact of depleting the cells of either 9G8 or SF2/ASF by siRNA. Similarly to what was observed with the luciferase mRNA, the data, presented in Supplementary Figure S2, show a reproducible diminution of the EB2-dependent cytoplasmic accumulation of the β-globin mRNA upon depletion of 9G8 or SF2/ASF. However, the impact of these depletions on EB2's capacity to induce accumulation of these mRNAs in the cytoplasm is not as drastic as that of SRp20.

Taken together, these data suggest that the effect of EB2 on the cytoplasmic accumulation of the β-globin mRNA is highly dependent on the presence of SRp20 but that rather than being recruited onto the mRNA by
Figure 7. SRp20 is required for the EB2-dependent cytoplasmic accumulation of human β-globin mRNA. (A) Immunoblots of HeLa cells co-transfected with the β1(-)2(−) reporter construct together with an EB2 expression plasmid as indicated in the figure. Cells were previously transfected with either a control siRNA (lanes 1 and 2) or a siRNA specific for SRp20 (lanes 3 and 4). The blots were probed with either a M2-Flag mAb to detect tagged Flag-EB2, an anti-SRp20 mAb or an anti-α-Tubulin as a control of total protein amounts. (B) Autoradiogram of an example of RT–PCR amplifications of human β-globin RNAs expressed in cells transfected as indicated in A, using the primer pair specific for human β-globin RNA (top panel) or a primer pair specific for actin RNA as internal control (bottom panel). (C) Quantification of the results of three experiments using a PhosphorImager. The error bars represent standard deviation.

specifically bound-SRp20, EB2 might mimic the effect of the 22-nt element by recruiting/stabilizing SRp20 onto the β-globin mRNA.

**EB2 increases SRp20 recruitment onto human β-globin RNA**

In order to test our above hypothesis that EB2 increases SRp20’s binding to β-globin RNA, we performed RNA-immunoprecipitation experiments. For this, HeLa cells, transiently transfected with the β1(-)2(−) reporter construct either alone or together with increasing amounts of an expression vector for EB2, were UV-irradiated to crosslink proteins to the RNA. SRp20-containing complexes were then immunoprecipitated with a specific anti-SRp20 antibody and RNA prepared from these immunoprecipitated fractions was analysed by RT–PCR. As can be seen in Figure 8A, the amount of β1(-)2(−) RNA co-immunoprecipitated with SRp20 increased proportionally with the amount of EB2 expressed in the cells. We also performed RNA-immunoprecipitation experiments using an anti-Flag antibody to immunoprecipitate Flag tagged-EB2 in the presence or absence of SRp20. Figure 8B shows that the amount of β1(-)2(−) RNA associated with EB2 remains unchanged when cells are depleted of SRp20. Taken together, these results indicate that EB2 bound to β-globin mRNA either recruits SRp20 onto the RNA or stabilizes SRp20’s association with this mRNA.

**EB2 counteracts the deleterious effect of SRp20 on cytoplasmic accumulation of EBV late viral mRNAs**

Since SRp20 has such a drastic effect on two model mRNAs that depend on EB2 for their efficient accumulation in the cytoplasm, we tested whether depletion of SRp20 also affected the EB2-dependent cytoplasmic accumulation of specific viral mRNAs. We have previously shown that the late BDLF1 and BFRF3 mRNAs are very poorly expressed following induction of the productive cycle of a recombinant EBV lacking the EB2-coding gene (18). We thus cloned these two genes under the control of the CMV promoter into a plasmid lacking intronic sequences (plasmids pCI-FlagBDLF1-i and pCI-FlagBFRF3-i respectively) (Figure 9A). These two constructs were transfected into HeLa cells together (or not) with an expression plasmid for EB2. Cells were previously transfected with either a SRp20-specific siRNA or a control siRNA. Cytoplasmic RNAs were purified and analysed by semi-quantitative RT–PCR (Figure 9B). As expected, the level of both BFRF3 and BDLF1 mRNAs were drastically increased in the presence of EB2 (compare lanes 2 to lanes 1 of each panel). Interestingly, SRp20 depletion also drastically enhanced the level of both BFRF3 and BDLF1 (compare lanes 3 to lanes 1 of each panel) and the presence of EB2 had only a minimal (or no) additive effect in the absence of SRp20. Nuclear RNAs were also quantified in these experiments and the results always mimicked what was seen in the cytoplasm (data not shown), indicating that the low level of cytoplasmic mRNA detected in the presence of SRp20 but in the absence of EB2 was not due to an accumulation of these mRNAs in the nucleus. These data strongly suggest that the main effect of EB2 is to counteract a deleterious effect of SRp20 on intronless viral mRNAs.

In order to investigate the role of SRp20 during the replicative cycle of EBV, we used the HEK293EBV cell line. HEK293EBV cells carry an EBV recombinant that constitutively expresses the Green Fluorescent Protein (GFP). The replicative cycle of the virus can be activated in these cells by ectopic expression of the immediate early EBV transactivator EB1 (also called Zta or zebra).
The amount of virus produced is then quantified following infection of Raji cells, by counting the number of GFP-expressing cells (43). We thus transfected HEK293EBV cells with a SRp20-specific siRNA or a control siRNA prior to transfection with the EB1 expression plasmid. As shown Figure 9C, virus production from cells in which SRp20 is down-regulated was reproducibly higher. This effect of SRp20 depletion on virus production was not unexpected since we have shown above, in the case of the two late viral mRNAs, BDLF1 and BFRF3, that SRp20 depletion itself induced the cytoplasmic accumulation of these two mRNAs, even in the absence of EB2. In accordance with these results, over-expression of SRp20 in HEK293EBV cells led to a diminution of virus production (data not shown). We then asked whether SRp20 depletion by itself could induce virus production in the absence of EB2. For this we repeated the above experiments with HEK293EBV-BMLF1KO cells that carry an EBV recombinant with the EB2-coding gene deleted (16). The results shown Figure 9D indicate that in the absence of EB2, SRp20 depletion was clearly not sufficient to increase virus production. It is interesting to note that when we trans-complemented the HEK293EBV-BMLF1KO cells depleted of SRp20 with an EB2 expression plasmid, we observed an increase in virus production very similar to that observed in the HEK293EBV cells treated with the SRp20 siRNA.

Taken together, these results suggest that one of the mechanisms by which EB2 stimulates the cytoplasmic accumulation of viral mRNAs is by counteracting the negative effect of SRp20 on these same mRNAs.

**DISCUSSION**

The EBV early protein, EB2, has been found to affect multiple cellular pathways involved in mRNA processing. It was thus interesting to better understand how EB2 interacts with the cellular network of proteins involved in mRNA processing. We approached this question by setting up a wide-scale yeast two-hybrid screen. Although probably not completely exhaustive, this screen allowed us to identify 42 putative cellular partners for EB2. Among these, only Sp100 (46) and RBM15b/OTT3 (21) had been previously described as being direct interactors of the viral protein. Sp100 is a component of PML bodies, which are disrupted upon EBV productive cycle reactivation (48). RBM15b/OTT3 directly interacts with NXF1 and acts at the post-transcriptional level to activate reporter gene expression (49). That we have now identified this protein in our Y2H screen argues for a direct interaction between hnRNPC and EB2. Interestingly, in our list of novel interactors, we found several proteins known for their implication in splicing (PUF60, SF3A2, SRSF1, SRSF3, SRSF7 and ZRSR2) including several members of the SR family of proteins. Previously, another member of the SR family, SFRS10, was also found to interact with EB2 in a yeast 2YH screen (46). Furthermore, SRp20

---

**Figure 8.** β-globin RNA-immunoprecipitation by anti-EB2 and anti-SRp20 antibodies. (A) HeLa cells were transfected with the β1(-)2(-) reporter construct together with increasing amounts (0, 0.5 or 1 μg) of Flag-tagged EB2 expression plasmid. After UV treatment of the cells, SRp20 containing complexes were immunoprecipitated using the anti-SRp20 mAb 7B4. RNA was then purified and the amount of specific β1(-)2(-) transcripts (panel a) or actin control mRNAs (panel b) co-immunoprecipitated was evaluated by semi-quantitative RT–PCR. The respective amounts of EB2 (panel c) and SRp20 (panel d) present in the samples used in the RNA-immunoprecipitations were evaluated by western blot analysis. (B) HeLa cells were transfected with the β1(-)2(-) reporter construct together with a Flag-tagged EB2 expression plasmid after transfection of the cells with an anti-SRp20 siRNA or a control siRNA as indicated. After UV treatment of the cells, EB2-containing complexes were immunoprecipitated using an anti-Flag M2 antibody. RNA was then purified and the amount of specific β1(-)2(-) transcripts (panel a) or actin control mRNA (panel b) co-immunoprecipitated was evaluated by semi-quantitative RT–PCR. The respective amounts of EB2 (panel c) and SRp20 (panel d) present in the samples used in the RNA-immunoprecipitations were evaluated by western blot analysis.
(SRSF3) was recently affinity purified in a complex with EB2 (27). The characterization of interactions between EB2 and several proteins involved in splicing was quite striking. Interestingly, these same three SR proteins were recently found to interact with IE4, the EB2 orthologue in varicella zoster (13) but the functional impact of these interactions was not studied. SRp20 also interacts with ICP27, the EBV orthologue in HSV1 (50). Both SRp20 and 9G8 co-localizes with ICP27 in HSV-infected cells and their down-regulation by use of specific siRNAs, reduces viral yields (51). However, the mechanisms by which SRp20 and 9G8 down-regulation exert this effect were not deciphered. We thus decided to study in more detail the interaction between EB2 and the three SR proteins identified in our screen.

We first confirmed the interaction between EB2 and the three SR proteins both by co-immunoprecipitation in mammalian cells and by GST–pull down. All experiments were realized in the presence of RNase showing that the interactions are RNA-independent. We also demonstrated the interaction in live cells, since over-expression of each of the three SR proteins is able to induce the nuclear re-localization of a cytoplasmic form of EB2 generated by mutating its two NLS (20). Although SF2/ASF, SRp20 and 9G8 are known to shuttle continuously between the nucleus and the cytoplasm (52) their apparent localization in cells is nuclear. EB2 is also a shuttling protein with a predominant nuclear localization: we previously showed that the cellular nuclear mRNA export protein NXF1 participates in the nuclear export

Figure 9. Impact of SRp20 depletion on the cytoplasmic accumulation of late viral mRNAs and on the production of virions. (A) Schematic representation of the pCI-BDLF1-i and pCI-BFRF3-i expression plasmids. (B) HeLa cells were co-transfected with pCI-BDLF1-i or pCI-BFRF3-i together or not with an EB2 expression plasmid. Cells were previously transfected with an anti-SRp20 siRNA or a control siRNA as indicated. Twenty-four hours later, cytoplasmic RNAs were prepared and subjected to RT–PCR using primer pairs specific for BDLF1 and BFRF3 respectively (panels a) or a primer pair specific for β-actin mRNA as internal control (panels b). (C) The EBV replicative cycle was induced in HEK293EBV cells previously treated with a SRp20 siRNA or a control siRNA, by transfection of an EB1 (BZLF1) expression plasmid. Cells supernatant were recuperated 72 h later and used to infect Raji cells. The number of GFP-expressing Raji cells was then evaluated 72 h later by FACS analysis. The efficiency of EB2 expression and SRp20 depletion was evaluated by western analysis and shown in the lower panels. (D) The EBV replicative cycle was induced in HEK293EBV-BMLF1KO cells previously treated with a SRp20 siRNA or a control siRNA, by transfection of an EB1 (BZLF1) expression plasmid together or not with an expression plasmid for EB2. Cells supernatant were recuperated 48 h later and used to infect Raji cells. The number of GFP-expressing Raji cells was then evaluated 72 h later by FACS analysis. The efficiency of EB2 expression and SRp20 depletion was evaluated by western blot analysis and shown in the lower panels.
of EB2 by binding to an NES sequence present in its N-terminal (24). Moreover, we have mapped two nuclear localization sequences (NLS) rich in KR residues that are responsible for nuclear import (20). However, mutation of the two NLS sequences of EB2 was not sufficient to completely inhibit translocation of EB2 from the cytoplasm to the nucleus. Our new data suggests that the interaction of EB2 with the SR proteins could result in the active translocation of EB2 from the cytoplasm to the nucleus or in its retention in the nucleus.

One of the main functions of EB2 in the productive cycle of EBV is to stimulate the cytoplasmic accumulation of most of the early and late viral mRNAs whose particularity is to be expressed from intronless genes (16,18,53). We thus tested the importance of the interaction between EB2 and the SR proteins for the cytoplasmic accumulation of mRNA generated from intronless genes. For this, we used two different reporter models: the first is based on an intronless reporter construct coding for the Renilla luciferase. We previously found that EB2 stimulates both cytoplasmic accumulation of the mRNA transcribed from this construct and ensures its efficient translation (25). The second model is a reporter construct carrying the human β-globin cDNA (4). Interestingly, by using siRNA we found that SRp20 depletion induced an increase in the cytoplasmic accumulation of both mRNAs and that in this case of SRp20 depletion, EB2 did not increase further the amount of mRNA in the cytoplasm. Since depletion of either 9G8 or SF2/ASF had only limited effect in the same kind of experiments, we decided to focus on SRp20. Interestingly, we found that SRp20 affected in a very similar manner two EBV late mRNAs originated from the BFRF3 and BDLF1 genes respectively. In all cases, depletion of SRp20 by itself induced a strong accumulation of the mRNA in the cytoplasm and EB2 had no or little additive effect on the amount of cytoplasmic mRNA. It is also important to note that when we quantified the amount of nuclear RNA for these specific transcripts, we observed that their abundance is very low (at least 1/20th of the cytoplasmic RNA) and varies in the same proportions as that of their corresponding cytoplasmic RNA. These data suggest that SRp20 exerts a negative effect on the amount of each of the four transcripts we have analysed in this study. This effect is likely to be nuclear since SRp20 depletion affects the amount of nuclear RNA in the same way as the amount of cytoplasmic RNA. In this context, it appears that one of the main functions of EB2 is to counteract this negative effect of SRp20.

How SRp20 so drastically induces a diminution of these four different mRNA species is still under study. However, several mechanisms can be invoked, such as induction of usage of cryptic splice sites, leading to the elimination of part of the original RNA, which renders the RNA undetectable by our PCR amplification, or destabilization of the mRNA. Our preliminary data suggest that both mechanisms could be involved in this effect of SRp20 (unpublished data).

The way EB2 counteracts these negative effects of SRp20 is still speculative but the data presented in this study by using a reporter construct carrying the human β-globin cDNA as a model, support the idea that by interacting with SRp20-specific mRNA targets, EB2 stabilizes SRp20 onto the mRNA. In effect, by using RNA-immunoprecipitations, we found that EB2 induced an increase association of SRp20 with the β-globin transcript. Interestingly, it was previously shown (4,54), that the RNA synthesized from this construct is inefficiently polyadenylated and poorly exported to the cytoplasm. Furthermore, cryptic splicing between the β-globin-coding sequence and vector sequences also contributed to lower the global amount of β-globin mRNA. The introduction in this construct of several copies of the mouse histone H2a 22-nt sequence that is specifically bound by the SR proteins, SRp20 or 9G8, was shown to promote inhibition of cryptic splicing and to enhance polyadenylation and nuclear export (4). By recruiting or stabilizing a direct interaction of SRp20 onto the β-globin mRNA, EB2 would appear to mimic the effect of the multimerized 22-nt element. SR protein-binding sites are largely degenerated and difficult to predict. Interestingly, wide-scale analyses have recently shown that SRp20 associates in vivo with a great number of mRNAs, including intronless mRNAs (55,56). Thus, SRp20 might interact at low affinity with several non-repertoriated sites on the β-globin mRNA. EB2 bound to the β-globin mRNA would then stabilize SRp20's association to this RNA resulting in a better polyadenylation of the transcript and inhibition of cryptic splicing. Furthermore, both SRp20 and EB2 can directly interact with NXF1 and thus lead to efficient nuclear export of their associated mRNPs (24,57).

In this study, we have described a mechanism by which EB2 recruits/stabilizes SR proteins onto mRNA generated from intronless genes. Since SR proteins are known for their role in both constitutive and alternative splicing, this suggests that EB2 might interfere with cellular mRNA splicing. Indeed, we have previously shown in different models that EB2 favours cytoplasmic accumulation of un-spliced mRNA with respect to spliced mRNAs generated from the same gene, especially when the spliced mRNAs are generated via cryptic splice sites, as is the case for the β-thalassemia gene (58). Moreover, Verma et al. (26) have recently shown that EB2 modulates the splicing of various cellular genes, including STAT1. In the case of STAT1, EB2 appears to change the ratio between two functionally distinct isoforms of STAT1 generated by alternative splicing (59) and SRp20 has been found to be involved in this modulation of STAT1 alternative splicing by EB2 (27). Whether this effect on cellular genes is important for EBV’s replication remains to be demonstrated.

Given the drastic effect of SRp20 depletion on several EB2-target mRNAs, including two late EBV mRNAs, we were of course interested in evaluating the effect of SRp20 depletion on the EBV replicative cycle itself. However, since one of the functions of EB2 is to counteract the negative effect of SRp20 on the accumulation of specific mRNA targets, we could expect that SRp20 depletion, in the presence of EB2, might not have any effect at all, which is exactly what we observed. In fact, we even observed a slight but reproducible increase in virus
production when SRp20 was down-regulated. In accordance, over-expression of SRp20 slightly diminished virus production (unpublished observations). It is interesting to note that SRp20 depletion has a very different impact on the EBV and HSV replicative cycle respectively since in HSV-infected cells SRp20 down-regulation was found to reduce viral yields (51). These results confirm once again that although these two orthologues are both necessary for the efficient cytoplasmic accumulation of their respective viral mRNAs, their mechanisms of action are clearly different which explains that ICP27 cannot trans-complement an EB2 compromised EBV recombinant (16).

By using cells infected by a virus recombinant with the EB2-coding region deleted, we asked whether SRp20 depletion could by itself allow the production of viruses in the absence of EB2, which was not the case. Again, this result was not unexpected since EB2 has also been reported to stimulate translation of its target mRNAs (25), which could be a limited step for the progression of the viral replicative cycle. Furthermore, although we have not as yet identified any, some of the early or late viral mRNAs might be more sensitive to a similar effect of other SR proteins. Interestingly, it has been recently shown that each SR protein accumulates in vivo on a distinct set of mRNAs (55,56). It is thus likely that SF2/ASF or 9G8 could fulfil the same function as SRp20 for EB2-mediated cytoplasmic accumulation of mRNA species other than those used in this study, depending on their pattern of association with different RNAs.

In conclusion we report here a novel mechanism by which the EBV protein EB2 favours the efficient accumulation of viral mRNAs generated from intronless genes by antagonizing the negative effect of SRp20 on these mRNAs.

SUPPLEMENTARY DATA

Supplementary Data are available at NAR Online: Supplementary Figures 1 and 2.

ACKNOWLEDGEMENTS

The authors thank Drs Y. Huang and J. A. Steitz for providing plasmids β1(−)β2(−), 1X-βG, 2X-βG and 4X-βG. The authors acknowledge the contribution of the 'Genetic Analysis and Vectorology' platform (B. Blanquier) and the 'Platim' microscope facilities of the SFR Biosciences Gerland-Lyon Sud (US8/UMS3444). Finally, the authors thank Dr R. Buckland for reading the manuscript.

FUNDING

Institut National de la Santé et de la Recherche Médicale (INSERM); Agence Nationale pour la Recherche [RPV06120CSA and RPV09056CSA to E.M.]; Pôle de Compétitivité Lyon-Biopôle; and Cluster de Recherche Rhône-Alpes en Infectiologie. Q.B. is recipient of a fellowship from the Ministère de la Recherche et de la Technologie (MRT) and of Association pour la Recherche sur le Cancer. F.J. is the recipient of a fellowship from the Ministère de la Recherche et de la Technologie (MRT) and the Fondation pour la Recherche Médicale (FRM); E.M. is a CNRS scientist. Funding for open access charge: INSERM.

Conflict of interest statement. None declared.

REFERENCES


